ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney DiseaseGlobeNewsWire • 05/15/23
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial ResultsGlobeNewsWire • 05/12/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International ConventionGlobeNewsWire • 05/09/23
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic HepatitisGlobeNewsWire • 05/04/23
ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public OfferingGlobeNewsWire • 05/01/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual ConferenceGlobeNewsWire • 04/27/23
ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public OfferingGlobeNewsWire • 04/26/23
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson's DiseaseGlobeNewsWire • 04/25/23
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100GlobeNewsWire • 04/24/23
ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical ImplantsGlobeNewsWire • 04/19/23
ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer's DiseaseGlobeNewsWire • 04/13/23
ZyVersa Therapeutics' CEO, Stephen C. Glover to Appear on Benzinga 'All Access'GlobeNewsWire • 04/12/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap ShowcaseGlobeNewsWire • 04/11/23
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer's DiseaseGlobeNewsWire • 04/10/23
ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial ResultsGlobeNewsWire • 04/03/23
ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/13/23
ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200GlobeNewsWire • 03/07/23
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare ConferenceGlobeNewsWire • 03/01/23
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual ConferenceGlobeNewsWire • 02/27/23
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer's Disease Following Traumatic Brain InjuryGlobeNewsWire • 02/23/23